Goodwin (JD Supra Taiwan)
-
Lotus and CKD Announce Biosimilar Collaboration
On September 19, 2020, Lotus Pharmaceutical Co., Ltd. (“Lotus”) and Chong Kun Dang Pharmaceutical Corp. (“CKD”) announced that they have entered into a commercialization agreement in connection with CKD’s biosimilar darbepoetin alfa, a second-generation epoetin indicated for the treatment of anemia associated with chronic renal failure. According to Lotus’ press release, the long-term strategic...
Request a trial to view additional results